Cyagen’s Post

Researchers developed a responsive Nd-MOF nanorod-based near-infrared cytosensor for real-time monitoring of HClO released from cells and tumors. The Nd-MOF nanorods, with SCy7 as a ligand, served as a photoactive material in a near-infrared photoelectrochemical cytosensor for MCF-7 cells, demonstrating a linear response. The cytosensor also monitored endogenous HClO released from stimulated cells, utilizing an aptamer and F127-coated Nd-MOF nanorods for NIR fluorescent imaging of HClO in cells and breast cancer-bearing mice. Source: https://lnkd.in/gST3fD4y #aptamer #tumor #medical #biology #lifescience

🎬That’s a wrap on #AAO2024 with the American Academy of Ophthalmology and Spherix Global Insights in #Chicago! 👀What an insightful event, and we are looking forward to sharing more information later this week on what we heard, and how Spherix is supporting #pharma in addressing key opportunities and challenges in the market. 📲Don’t hesitate to reach out directly to me or Bob Shewbrooks if you’d like to be added to the list and/or do a post-meeting debrief, layering in Spherix #marketresearch onto all this great information. 🌎Perspective is everything. #ophthamology #biotech #unmetneed #insights #lifesciences #perspective

😉 ETAP-Lab at a glimpse 💡Did you know? ETAP-Lab is made of 3 laboratories of excellence offering pharmacology and preclinical research services, as well as scientific expertise, to the pharmaceutical and biotech industries.   👩🔬👨🔬Our specialists advise and support you in #Dermatology, #Cardiology and #Neurology (specifically in neurodegenerative diseases, stroke and psychopharmacology).   🔔Follow ETAP-Lab - Preclinical Efficacy CRO, #StrokAlliance and SYNCROSOME - Cardiovascular Preclinical expert to cover all the group's activities.   ➡️ Keep up to date with scientific news in our specialty areas and our latest preclinical models ➡️ Meet our experts at conferences around the world ➡️ Discover the progress of our research and innovation programs   #preclinicalresearch #MadeInFrance #healthtech

A new study found evidence that suggested that pegcetacoplan (Syfovre, Apellis Pharmaceuticals) may delay atrophy of the retinal pigment epithelium (RPE) and photoreceptors in patients with geography atrophy (GA), reported Dun Jack Fu, PhD. He and colleagues undertook this post hoc analysis of data from 2 phase 3 clinical trials of pegcetacoplan. Spectral-domain optical coherence tomography (SD-OCT) has been the go-to technology to evaluate GA; however, according to the authors, determining the changes in GA progression, based on the Consensus of Atrophy Meetings (CAM) group, requires manual segmentation of OCT volume scans, which is time consuming, labor intensive, and limited by interrater variability. The authors suggested that the process can be stream-lined by using automated image segmentation algorithms. They recently developed a deep-learning based platform that uses CAM-defined OCT features to detect and quantify GA and its components. Read More: https://ow.ly/j0Em50RSp6F

We made a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.    The poster, entitled “VECTrans® technology: a powerful delivery approach to significantly enhance efficacy of therapeutic oligonucleotides in retina cells”, outlines a study assessing Vect-Horus’ proprietorial VECTrans® technology. This is based on the specific design and optimization of molecular vectors that, once joined to a payload, enable its delivery to target specific organs in the body.     The study showed that these vectors have the potential to improve delivery of medication to the eye. It’s a good demonstration of the technology’s potential, building further on our two recent major licensing agreements, with Novo Nordisk and Ionis Pharmaceuticals, Inc.     With thanks to Stéphane Girard, PhD, Ophthalmology Department Manager, and Sebastien Roux, PhD, Neuroscientist, for their work on this.    #biotech #vectors #drugdevelopment #breakingbarriers #opthalmology #arvo 

🚀Exciting developments from EHA 2024! Dr Hanne Norseth from the Oslo Myeloma Center presented the results of the phase I/II TG01 study. This study explores the safety and efficacy of the TG01/QS-21 vaccine in patients with KRAS or NRAS mutations. While the vaccine was well-tolerated, further evaluation is needed to determine its clinical efficacy. Stay tuned for more updates on this innovative approach in multiple myeloma treatment. For all EHA 2024 videos, find the link in the comments! 👇 #MediMix #Hematology #MultipleMyeloma #Innovation

𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐦𝐨𝐫𝐩𝐡𝐨𝐥𝐨𝐠𝐲 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐜𝐞𝐥𝐥𝐮𝐥𝐚𝐫 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐢𝐧 𝐡𝐞𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 Companies worldwide are augmenting their product portfolios, enhancing efficiency and standardization in the testing workflow, and increasing clinical value through improved precision of cell morphology classification. Read the exclusive story: https://lnkd.in/gxuPChYG #product #portfolios #testing #workflow #morphology #efficiency #hematology #analyzers #diagnosis #treatment #algorithms #digital #instruments #market

The answer to yesterday’s #ClinicalChallenge question is: B. The small molecule pyruvate kinase activator mitapivat was approved in 2022 for people with anemia based on improvements in hemoglobin over 24 weeks. An extension of the original study to 96 weeks demonstrated that mitapivat also reduces iron overload, with significant reduction in liver iron and decrease in inflammatory markers. View the related What's New topic in #UpToDate: https://ow.ly/Abis50SPoXW #hematology #meded

Light-Sheet Microscopy awardee Michael Welte, PhD published in Advanced Healthcare Materials: "Sided Stimulation of Endothelial Cells Modulates Neutrophil Trafficking in an In Vitro Sepsis Model." https://ow.ly/FyHz50Tm8Av #published #phd #lightsheet #microscopy #article #sepsis #therapeutics #biology #molecularbiology #cellbiology